CERENIS ANNOUNCES FINANCING FROM INVESTMENT FUNDS, MANAGEMENT, ITS BOARD OF DIRECTORS AND ITS ONCOLOGY SCIENTIFIC ADVISORY BOARD

Toulouse, FRANCE, Lakeland, UNITED-STATES, July 26, 2018, 8.00 CEST – Cerenis Therapeutics
(FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company
dedicated to the discovery and development of HDL-based innovative therapies for treating
cardiovascular, metabolic diseases, and new HDL-based vectors for the targeted drug delivery in the
oncology field announces a capital increase of more than one million euros for the financing of its
immuno-oncology activities.
Terms of issuance
The Company is issuing 638,753 new shares at a price of 1.78 euros per share (a discount of 5%
compared to the weighted average of the 10 trading days preceding the decision of the Board of
Directors dated of July 16, 2018 subdelegating its jurisdiction).
This issuance is part of a capital increase with cancellation of preferential subscription rights for the
benefit of persons belonging to specific categories1
, decided today by the Chief Executive Officer,
acting on the delegation of authority from the Board of Directors on the basis of the prior delegation
granted by the General Meeting of 25 June 2018 pursuant to the terms of its twenty-sixth
extraordinary resolution.
The total amount of the capital increase is 1,136,980.34 euros (of which 31,937.65 euros in nominal
value, together with an issue premium of 1,105,042.69 euros).
The number of shares thus issued represents approximately 3.37% of the number of shares
outstanding (post-issue). By way of illustration, a shareholder who held a number of shares
representing 1% of the share capital of Cerenis prior to the issue, now represents 0.97% of the share
capital.